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Abstract Thymoquinone is a known inhibitor of neu-
roinflammation. However, the mechanism(s) involved in its
action remain largely unknown. In this study, we investi-
gated the roles of cellular reactive oxygen species (ROS),
50 AMP-activated protein kinase (AMPK) and sirtuin 1
(SIRT1) in the anti-neuroinflammatory activity of thymo-
quinone. We investigated effects of the compound on ROS
generation in LPS-activated microglia using the fluorescent
20,70-dichlorofluorescin diacetate (DCFDA)-cellular ROS
detection. Immunoblotting was used to detect protein levels
of p40phox, gp91phox, AMPK, LKB1 and SIRT1. Addi-
tionally, ELISA and immunofluorescence were used to
detect nuclear accumulation of SIRT1. NAD?/NADH
assay was also performed. The roles of AMPK and SIRT1
in anti-inflammatory activity of thymoquinone were
investigated using RNAi and pharmacological inhibition.
Our results show that thymoquinone reduced cellular ROS
generation, possibly through inhibition of p40phox and
gp91phox protein. Treatment of BV2 microglia with thy-
moquinone also resulted in elevation in the levels of LKB1
and phospho-AMPK proteins. We further observed that
thymoquinone reduced cytoplasmic levels and increased
nuclear accumulation of SIRT1 protein and increased
levels of NAD?. Results also show that the anti-inflam-
matory activity of thymoquinone was abolished when the
expressions of AMPK and SIRT1 were suppressed by
RNAi or pharmacological antagonists. Pharmacological
antagonism of AMPK reversed thymoquinone-induced
increase in SIRT1. Taken together, we propose that thy-
moquinone inhibits cellular ROS generation in LPS-acti-
vated BV2 microglia. It is also suggested that activation of
both AMPK and NAD?/SIRT1 may contribute to the anti-
inflammatory, but not antioxidant activity of the compound
in BV2 microglia.
Keywords Thymoquinone  AMPKa  ROS  SIRT1 
Neuroinflammation
Background
Accumulating evidence suggests that there is a strong link
between oxidative stress and inflammation. An unbalanced
redox state is known to contribute to the pathogenesis of
inflammatory conditions, including ageing [1]. Further-
more, it is now widely accepted that inflammation triggers
the generation of elevated levels of cellular reactive oxygen
species that cause cellular oxidative damage [2]. On the
other hand, inflammatory cells respond to oxidative stress
by releasing various NF-jB-mediated pro-inflammatory
mediators [3]. Oxidative stress has also been linked to
neuroinflammation. Accumulating evidence indicates that
reactive oxygen species (ROS) produced by the microglia
have a significant impact on adjacent neurons, as well as
modulating microglial activity [4]. It has been shown that
the activated microglia M1 phenotype is associated with
elevated levels of NADPH oxidase (NOX)-dependent ROS
generation [5]. Consequently, oxidative stress is now
recognised as an important contributor to
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neuroinflammation, and its resultant neuronal damage in
neurodegenerative disorders.
Adenosine monophosphate-activated protein kinase
(AMPK) is a well-known sensor of energy balance by
responding to ATP-depleting processes such as cellular
stress [6]. Recent evidence now suggests that AMPK reg-
ulates inflammatory responses [7]. AMPK has been shown
to be critical for inducing macrophages from a pro-in-
flammatory to anti-inflammatory phenotype during
inflammation [8]. AMPK activation therefore appears to be
a potential strategy for inhibiting inflammation.
Sirtuin 1 (SIRT1) is a member of the sirtuin family
which has been linked to cellular processes, including
neuroinflammation. SIRT1 is responsible for deacetylation
of transcription factors, including p65 subunit of NF-jB
during inflammation [9–14]. Due to its negative modula-
tory effect on inflammation, activation of SIRT1 appears to
be critical to achieving anti-inflammatory activity.
Thymoquinone (Fig. 1) is the main constituent of the oil
obtained from the seeds of Nigella sativa (black cumin
seed oil), and has been widely reported to produce anti-
inflammatory activity [15–18]. This compound has been
shown to inhibit neuroinflammation in mix glial cells [19]
and BV2 microglia [20–22].
In this study, we report that thymoquinone activation of
both AMPK and SIRT contribute to inhibition of neu-
roinflammation and cellular ROS by thymoquinone in BV2
microglia.
Methods
Cell culture
BV2 mouse microglia cell line ICLC ATL03001 (Interlab
Cell Line Collection, Banca Bilogica e Cell Factory, Italy)
was maintained in RPMI1640 medium with 10% fetal
bovine serum (FBS) (Sigma), 2 mM L-glutamine (Sigma),
100 U/mL penicillin and 100 mg/mL streptomycin
(Sigma) in a 5% CO2 incubator.
Intracellular cellular ROS production
Determination of intracellular reactive oxygen species
(ROS) levels in BV2 microglia was performed using the
fluorescent 20,70-dichlorofluorescin diacetate DCFDA-cel-
lular reactive oxygen species detection assay kit (Abcam).
Briefly, BV2 microglia were incubated with 10 lM
DCFDA for 30 min at 37 C. After removal of excess
DCFDA, the cells were washed and then exposed to LPS
(100 ng/mL) for 4 h at 37 C in the presence or absence of
thymoquinone (2.5–10 lM). Intracellular production of
ROS was measured by the fluorescence detection of
dichlorofluorescein (DCF) as the oxidised product of
DCFH on a microplate reader with an excitation wave-
length of 485 nm and emission wavelength of 535 nm.
Immunoblotting
For Western blotting, 20–40 lg of total protein from cell
samples was subjected to SDS-PAGE under reducing
conditions. Proteins were then transferred onto
polyvinylidene fluoride (PVDF) membranes (Millipore).
The membranes were blocked for 1 h at room temperature
and then incubated overnight at 4 C with primary anti-
bodies. Primary antibodies used were rabbit anti-SIRT1
(Santa Cruz), rabbit anti-phospho-AMPKa (Santa Cruz),
rabbit anti-total AMPKa (Santa Cruz), rabbit anti-LKB1
(Santa Cruz) and rabbit anti-actin (Sigma). Primary anti-
bodies were diluted in Tris-buffered saline (TBS), con-
taining 0.1% Tween 20 (TBS-T) and 1 or 5% BSA.
Membranes were incubated with the primary antibody
overnight at 4 C. After extensive washing (three times for
15 min each in TBS-T), proteins were detected by incu-
bation with Alexa Fluor 680 goat anti-rabbit secondary
antibody (1:10,000; Life Technologies) at room tempera-
ture for 1 h. Detection was done using a LICOR Odyssey
Imager. All Western blot experiments were carried out at
least three times.
SIRT1 ELISA
BV2 microglia were seeded in a 6-well plate for 48 h.
Thereafter, cells were treated with 2.5–10 lM thymo-
quinone for 24 h. Following treatment, nuclear extracts
were prepared and analysed for levels or SIRT1 using a
mouse SIRT1 ELISA kit (Abcam), according to the man-
ufacturer’s instructions.
NAD1/NADH quantification
BV2microglia were seeded in a 6-well plate and treated with
thymoquinone (2.5–10 lM) for 24 h. Cell lysates were
collected with 400 lL of NADH/NAD extraction bufferFig. 1 Structure of thymoquinone
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(Abcam). Quantification of NADH and NAD, and their ratio
was carried out with a colorimetric NAD/NADH assay kit
(Abcam), according to the manufacturer’s instructions.
RNA interference
Small interfering RNA (siRNA) targeted at mouse AMPK
(Santa Cruz Biotechnology) was used to knockout AMPK.
BV2 cells were cultured and incubated at 37 C in a 5%
CO2 incubator until 70–80% confluent. Cells were then
seeded out in a 6-well plate at a density of 1 9 106 cells/
well. AMPK siRNA duplex (10 lM) were diluted in Opti-
MEM medium (Thermo Scientific). Lipofectamine
RNAiMAX transfection reagent (Thermo Scientific) was
also diluted in Opti-MEMmedium. Thereafter, the diluted
siRNA was added to diluted lipofectamine RNAiMAX
reagent (1:1 ratio). The siRNA-lipid complex was then
incubated at room temperature for 5 min. The complex was
thereafter added to cells and incubated for a further 24 h.
Following transfection, media was changed in transfected
cells to complete media and incubated for a further 18 h.
Effects of thymoquinone (10 lM) on NO, PGE2, TNFa, IL-
1b, IL-6 and ROS production in LPS-stimulated control
siRNA and AMPK siRNA-transfected BV2 cells were then
determined. Similar procedures were used to transfect BV2
cells with mouse SIRT1 siRNA (Santa Cruz Biotechnol-
ogy), prior to experiments to evaluate effects of thymo-
quinone (10 lM) on NO, PGE2, TNFa, IL-1b, IL-6 and
ROS production in LPS-stimulated BV2 cells.
Evaluation of the effects of AMPK inhibitor
on the anti-inflammatory and antioxidant activities
of thymoquinone in LPS-activated BV2 microglia
We further investigated whether pharmacological inhibi-
tion of AMPK with compound C (Sigma) would affect
anti-inflammatory and antioxidant activities of thymo-
quinone in LPS-activated microglia. Cultured BV2
microglia were treated with compound C (10 lM). One
hour later, cells were treated with thymoquinone (10 lM)
prior to stimulation with LPS (100 ng/mL) for a further
24 h. Culture supernatants were analysed for levels of
TNFa, IL-6, IL1b, NO, PGE2. Generation of cellular ROS
was determined using the DCFDA method.
Evaluation of the effects of SIRT1 inhibitor
on the anti-inflammatory and antioxidant activities
of thymoquinone in LPS-activated BV2 microglia
Pharmacological inhibition of SIRT1 using EX527 (Tocris)
was used to determinewhether SIRT1 is required for the anti-
inflammatory and antioxidant actions of thymoquinone in
the microglia. BV2 cells were treated with EX527 (1 lM)
followed by thymoquinone (10 lM) prior to stimulation
with LPS (100 ng/mL) for 24 h. Culture supernatants were
analysed for levels of TNFa (Biolegend, UK), IL-6 (Biole-
gend, UK), IL1b (Biolegend, UK), NO (Promega, UK),
PGE2 (Arbor Assays, USA). Generation of cellular ROSwas
determined using the DCFDA method (Abcam, UK).
Determination of SIRT-1 activation
by thymoquinone in the presence of AMPK inhibitor
We were also interested in the role played by AMPK in the
activation of SIRT1 by thymoquinone. Cultured BV2
microglia were therefore treated with thymoquinone
(10 lM) in the presence and absence of the AMPK inhi-
bitor, compound (10 lM). Thereafter, protein levels of
nuclear SIRT1 were determined using immunoblotting and
ELISA. Also, levels of NAD?/NADH were quantified in
cell extracts.
Statistical analysis
Values of all experiments were represented as a
mean ± SEM of at least 3 experiments. Values were
compared using one-way ANOVA followed by a post hoc
Student Newman–Keuls test.
Results
Generation of NADPH oxidase (NOX)-dependent
cellular reactive oxygen species (ROS) in LPS-
activated BV2 microglia was inhibited
by thymoquinone
Generation of intracellular ROS is a major component of
LPS-induced neuroinflammation. We therefore investi-
gated the effect of thymoquinone on LPS-induced gener-
ation of ROS in BV2 microglia. Following a 24-h
stimulation of microglia with LPS, there was a marked
generation of intracellular ROS (Fig. 2a). On treating cells
with thymoquinone (2.5, 5 and 10 lM), we observed a
significant (p\ 0.001) and concentration-dependent
attenuation of intracellular ROS generation, suggesting that
thymoquinone is antioxidant in LPS-activated microglia.
Following our observation that thymoquinone produced
antioxidant activity against LPS-induced ROS generation,
we were interested in establishing whether this effect was
mediated by targeting the NADPH oxidase (NOX)
enzymes. To investigate this, we carried out western blot-
ting for the cytoplasmic p-p40phox and membrane-bound
gp91phox NOXs in BV2 microglia stimulated with LPS in
the presence of thymoquinone. Stimulation of BV2 cells
for 24 h resulted in elevation of both p-p40phox and
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gp91phox proteins (Fig. 2b, c). Treatment of cells with
thymoquinone (2.5–10 lM) prior to LPS, resulted in sig-
nificant reduction of both NADPH oxidases.
Thymoquinone activates LKB-1/AMPKa in BV2
microglia
It has been suggested that AMPK contributes to the
antioxidant mechanisms by stimulating Nrf2 signalling in
immune cells such as RAW 264.7 macrophages [23].
Zimmermann et al. have also shown that activation of
AMPK enhances Nrf2/HO1 signalling. We therefore aimed
to evaluate the effects of thymoquinone on AMPK and its
upstream kinase LKB-1 in BV2 microglia [24]. Prelimi-
nary immunoblotting to determine time-point of AMPK
activation by thymoquinone (10 lM) shows that maximum
activation was detected at 12 h (Fig. 3a). Western blotting
experiments show that treatment with thymoquinone
(2.5 lM) for 12 h produced a slight increase in the levels
of phosphorylated AMPKa. On increasing the concentra-
tion of thymoquinone to 5 and 10 lM, there was*1.7 and
*2.3-fold elevation in the levels of the phosphorylated
AMPKa, respectively (Fig. 3b). LKB-1 is a kinase that is
known to directly phosphorylate and activate AMPK.
Therefore, we evaluated the effect of thymoquinone treat-
ment on LKB-1 protein in BV2 microglia. Our experiments
show that incubating BV2 microglia with thymoquinone (5
and 10 lM) for 12 h resulted in an increase in LKB-1
protein in a similar fashion as AMPKa (Fig. 3c).
AMPK siRNA transfection and compound C
treatment reversed anti-inflammatory effect
of thymoquinone in LPS-activated BV2 microglia
Based on our observation that thymoquinone could activate
AMPKa, we became interested in elucidating the role of
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Fig. 2 Thymoquinone inhibits NADPH oxidase-mediated ROS gen-
eration in LPS-activated BV2 microglia. a BV2 cells were treated
with vehicle or thymoquinone (2.5–10 lM) for 30 min prior to LPS
stimulation for 24 h. ROS generation was measured in live cells by
the fluorescence detection of dichlorofluorescein. (Mean ± SEM;
***p\ 0.001; one-way ANOVA with post hoc Student Newman–
Keuls test). b BV2 cells were treated with vehicle or thymoquinone
(2.5–10 lM) for 30 min prior to LPS stimulation for 24 h. Cell
lysates were analysed using immunoblotting for p-p40phox and actin.
Representative blots and densitometric analyses of three independent
experiments are shown (Mean ± SEM; **p\ 0.01; one-way
ANOVA with post hoc Student Newman–Keuls test). c BV2 cells
were treated with vehicle or thymoquinone (2.5–10 lM) for 30 min
prior to LPS stimulation for 24 h. Membrane extracts were analysed
using immunoblotting for gp91phox and actin. Representative blots
and densitometric analyses of three independent experiments are
shown (Mean ± SEM; **p\ 0.01, ***p\ 0.001; one-way with
ANOVA post hoc Student Newman–Keuls test)
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this activation on the anti-inflammatory activity of the
compound in BV2 microglia. AMPKa siRNA-transfected
cells were treated with 10 lM thymoquinone, followed by
LPS (10 lM) stimulation for 24 h. Analyses of culture
supernatants revealed that thymoquinone (10 lM) pre-
vented the release of pro-inflammatory mediators from
control siRNA-transfected BV2 microglia (Fig. 4a–e).
Similarly, thymoquinone suppressed binding of activated
NF-jB to its consensus binding sites on the DNA (Fig. 4f).
In AMPKa siRNA-transfected cells however, the ability of
thymoquinone to inhibit NF-jB-mediated neuroinflamma-
tion was significantly diminished (p\ 0.05), in compar-
ison with control siRNA-transfected cells (Fig. 4a–f).
Similarly, reduction of LPS-induced ROS generation in
BV2 cells was significantly reversed when cells were
transfected with AMPK siRNA (Fig. 4g). Western blotting
analyses show that AMPK protein was efficiently reduced
in AMPK siRNA-transfected cells (Fig. 4h).
To confirm our observations, we treated BV2 cells
with a known inhibitor of AMPK, (compound C) prior to
thymoquinone treatment and subsequent stimulation with
LPS for 24 h. Interestingly, inhibition of inflammatory
mediator (TNFa, IL-6, IL-1b, NO, PGE2) release as well
as NF-jB DNA binding by thymoquinone (10 lM) were
significantly (p\ 0.05) reversed in the presence of
compound C (10 lM) (Fig. 5a–f). In Fig. 5g, results show
that the effect of thymoquinone on LPS-induced ROS
generation in BV2 cells was lost in the presence of
compound C.
Thymoquinone induces NAD1-dependent nuclear
localisation of SIRT1 in BV2 microglia
It is now established that SIRT1 deacetylates p65, resulting
in the inhibition of the transcriptional ability of NF-jB
[11]. Based on our earlier observation that thymoquinone
attenuated LPS-induced p65 acetylation in BV2 microglia,
we wanted to find out whether the compound could also be
activating SIRT1. Immunoblotting results in Fig. 6a shows
that treating BV2 microglia with thymoquinone
(2.5–10 lM) for 24 h resulted in significant (p\ 0.001)
accumulation of SIRT1 protein in the nucleus. This was
shown to correspond to a concentration-dependent reduc-
tion in levels of this sirtuin from the cytoplasm (Fig. 6b).
Immunofluorescence data (Fig. 6c) show an increase in
SIRT1 immunostaining in BV2 microglia treated with
thymoquinone (5 and 10 lM). Similar results were
obtained in a mouse SIRT1 ELISA, which shows *1,
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Fig. 3 Thymoquinone activates AMPKa (a, b) and its upstream
kinase LKB1 (c). BV2 microglia were treated with thymoquinone
(2.5–10 lM) for 12 h. Cell lysates were analysed using immunoblot-
ting for phospho-AMPKa and total AMPKa (a), LKB1 and actin (b).
Representative blots and densitometric analyses of three independent
experiments are shown (Mean ± SEM; **p\ 0.01, ***p\ 0.001;
one-way ANOVA with ANOVA post hoc Student Newman–Keuls
test)
Mol Cell Biochem
123
*1.3 and *1.5-fold increase in SIRT1 in cells treated
with 2.5, 5 and 10 lM thymoquinone, respectively
(Fig. 6d).
We also investigated the effect of thymoquinone on
NAD?/NADH ratio in BV2 microglia, and showed that
treatment with the compound resulted in statistically
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Fig. 4 Inhibition of neuroinflammation by thymoquinone is depen-
dent on AMPKa. Control siRNA- and AMPKa siRNA-transfected
BV2 cells were pre-treated with thymoquinone (10 lM) prior to
stimulation with LPS (100 ng/ml) for 24 h. Cells were analysed for
TNFa (a), IL-6 (b), IL-1b (c), nitrite (d) PGE2 (e) and ROS (f). In
g nuclear extracts from cells were added to 96-well plates to which an
oligonucleotide containing the NF-jB consensus site (50-
GGGACTTTCC-30) has been immobilised, followed by addition of
NF-jB and HRP-conjugated antibodies. Absorbance was read in a
microplate reader. Western blot experiments on cell extracts to
determine knockout efficiency (h). (Mean ± SEM; **p\ 0.01,
***p\ 0.001 thymoquinone ? LPS treatment compared with LPS
alone in control siRNA-transfected cells; #p\ 0.05, ###p\ 0.001,
thymoquinone ? LPS treatment in AMPK siRNA-transfected cells
compared with thymoquinone ? LPS treatment in control siRNA-
transfected cells; one-way ANOVA with ANOVA post hoc Student
Newman–Keuls test)
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Fig. 5 Inhibition of neuroinflammation by thymoquinone was abol-
ished in the presence of compound C. BV2 cells were treated with
compound C (10 lM), followed by thymoquinone (10 lM) and LPS
(100 ng/ml) for 24 h. Cells were analysed for TNFa (a), IL-6 (b), IL-
1b (c), nitrite (d), PGE2 (e) and ROS (f). In g nuclear extracts from
cells were added to 96-well plates to which an oligonucleotide
containing the NF-jB consensus site (50-GGGACTTTCC-30) has
been immobilised, followed by addition of NF-jB and HRP-
conjugated antibodies. Absorbance was read in a microplate reader.
(Mean ± SEM; **p\ 0.01, ***p\ 0.001 compared with LPS
stimulation; #p\ 0.05, ##p\ 0.01, ###p\ 0.001, compound
C ? thymoquinone ? LPS treatment compared with thymo-
quinone ? LPS treatment; one-way ANOVA with ANOVA post
hoc Student Newman–Keuls test)
Mol Cell Biochem
123
01
2
3
4
Thymoquinone (μM)       0              2.5         5            10
***
N
uc
le
ar
 S
IR
T1
 f
ol
d 
in
cr
ea
se
(c
om
pa
re
d 
w
it
h 
co
nt
ro
l)
A B 
0
1
Thymoquinone (μM)                 0           2.5            5             10
**
Cy
to
pl
as
m
ic
 S
IR
T1
SI
RT
1/
Ac
tin
C 
0
1
2
3
4
Thymoquinone (μM)         -             2.5           5            10
*
N
uc
le
ar
 S
IR
T1
 F
ol
d 
In
cr
ea
se
 (C
om
pa
re
d 
w
ith
 c
on
tr
ol
)D
0
2
4
Thymoquinone (μM)                 0           2.5            5             10
**
***
NA
D
+ /
NA
DH
 R
at
io
E
Fig. 6 Thymoquinone activates SIRT1 in BV2 microglia. a BV2
cells were treated with vehicle or thymoquinone (2.5–10 lM) for
12 h. Nuclear extracts were analysed using immunoblotting for SIRT-
1 and lamin B. Representative blots and densitometric analyses of
three independent experiments are shown (Mean ± SEM;
***p\ 0.001; one-way ANOVA). b BV2 cells were treated with
vehicle or thymoquinone (2.5–10 lM) for 12 h. Cytoplasmic extracts
were analysed using immunoblotting for SIRT-1 and actin. Repre-
sentative blots and densitometric analyses of three independent
experiments are shown (Mean ± SEM; **p\ 0.01, ***p\ 0.001;
one-way ANOVA with ANOVA post hoc Student Newman–Keuls
test). c Immunofluorescence showing nuclear SIRT1 following
treatment of BV2 cells with thymoquinone for 12 h. d BV2 cells
were treated with vehicle or thymoquinone (2.5–10 lM) for 12 h.
Nuclear extracts were analysed using mouse ELISA for SIRT1.
(Mean ± SEM; *p\ 0.001; one-way ANOVA). e Thymoquinone
increases levels of NAD? in BV2 microglia. (Mean ± SEM;
**p\ 0.01, ***p\ 0.001; one-way ANOVA with ANOVA post
hoc Student Newman–Keuls test)
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significant (p\ 0.01) and concentration-dependent
increase in levels of NAD? (Fig. 6e).
Transfection of BV2 microglia with SIRT1 siRNA
and treatment with EX527 reversed anti-
inflammatory action of thymoquinone
Following observations suggesting that thymoquinone
inhibits acetylation of p65 during neuroinflammation as
well as activating SIRT1, we were interested in investi-
gating whether direct activation of SIRT1 contributes to the
anti-inflammatory action of the compound. Results in
Fig. 7a–e show that anti-inflammatory effects of thymo-
quinone on the production of TNFa, IL-6, IL-1b, nitrite
and PGE2 were significantly (p\ 0.05) abolished follow-
ing transfection of LPS-activated BV2 microglia with
mouse SIRT1 siRNA. Similarly, inhibition of NF-jB DNA
binding by the compound was diminished in the presence
of SIRT1 siRNA (Fig. 7f). Interestingly, we observed that
the ability of the compound to reduce ROS production
following LPS stimulation was unaffected by SIRT1
siRNA transfection (Fig. 7g).
We proceeded to carry out experiments on the role of
pharmacological inhibition of SIRT1 on anti-inflammatory
effect of thymoquinone by pre-treating BV2 cells with
EX527 (1 lM) prior to thymoquinone treatment (10 lM),
and followed by stimulation with LPS. Results in Fig. 8a–f
show that NF-jB-mediated anti-inflammatory effects of
thymoquinone on LPS-induced neuroinflammation were
diminished when SIRT1 was inhibited by EX527. How-
ever, EX527 treatment did not interfere with antioxidant
action of thymoquinone on LPS-induced ROS generation
(Fig. 8g).
Thymoquinone activates SIRT1 through AMPK-
dependent mechanisms
Treatment of BV2 microglia with thymoquinone (10 lM)
resulted in a significant (p\ 0.05) increase in nuclear
accumulation of SIRT1 (Fig. 9a, b). However, this effect
was lost when the cells were exposed to compound C
(10 lM) prior to treatment with thymoquinone. Similarly,
there was increase in NAD? levels produced as a result of
thymoquinone treatment was diminished in the presence of
compound C (10 lM) (Fig. 9c).
Discussion
Activation of microglia during neuroinflammation is
known to result in the generation of ROS by a process that
is facilitated by the NADPH oxidase enzymes [25, 26].
Furthermore, excessive production of ROS through
NADPH oxidase is known to be responsible for neuroin-
flammation and neurodegeneration [27]. We show that
thymoquinone produced a marked reduction in ROS gen-
eration induced by LPS stimulation in BV2 microglia,
suggesting that the compound is able to attenuate ROS
generation in response to neuroinflammation. It is known
that activated microglia cells are associated with elevated
levels of NADPH oxidase (NOX)-dependent ROS gener-
ation [5]. NOX is a multi-subunit enzyme complex which
transfers electrons from NADPH to molecular oxygen,
forming O2
-. Under resting conditions, the different sub-
units of this complex are localised in the cytosol (p40phox,
p47phox and p67phox) and in the cell membrane (p22phox and
gp91phox). However, following stimulation of the micro-
glia, the complex is assembled in the plasma membrane
[27]. Once we established that thymoquinone reduced ROS
generation in activated microglia, we then proceeded to
show that thymoquinone produced a reduction in elevated
levels of p-p40phox and gp91phox proteins in LPS-stimulated
microglia, suggesting that an inhibition of these NOX
enzymes contribute to the inhibitory effects of the com-
pound on ROS generation during neuroinflammation.
Consistent with our findings, thymoquinone was shown in
other studies to reduce ROS generation in inflammation
[28, 29].
There have been suggestions in the scientific literature
linking AMPK activation to inhibition of inflammation
[30]. Our results reveal that thymoquinone treatment
increased the levels of phosphorylated AMPKa and its
upstream kinase LKB1 in the microglia, suggesting that
this compound activates the LKB1/AMPKa signalling
pathway in the microglia. Thymoquinone has earlier been
reported to produce anti-inflammatory effect as well as
enhancing the phosphorylation AMPK and LKB1 in a
mouse model of fibrosis [31]. In another study reported by
Yang et al., the compound activated AMPK in hepatic
stellate cells [32]. To our knowledge, this is the first report
showing that thymoquinone activates AMPK in the
microglia.
Based on reports showing inhibition of neuroinflam-
mation by thymoquinone [20–22], and our observation on
the inhibition of cellular ROS generation in LPS-activated
microglia, we then asked whether there was a relationship
between these activities and AMPK activation by the
compound. Interestingly, it was revealed that transfection
with AMPKa siRNA as well as pre-treatment with AMPK
inhibitor (Compound C) resulted in the loss of anti-in-
flammatory and ROS inhibitory activities of thymoquinone
in LPS-activated BV2 microglia. Studies have linked
AMPK to inflammation and redox mechanisms. For
example, studies reported by Lin et al. [33] and Tsai et al.
[7] suggest that lycopene and caffeic acid phenethyl ester
(CAPE) produce anti-neuroinflammatory effect through
Mol Cell Biochem
123
0200
400
600
800
*
#
Thymoquinone (10 μM)          -          -           +          -           +
LPS (100 ng/ml)                     -          +          +          +          +
SIRT1 siRNA                          -           -          -           +          +
Control siRNA                       +          +         +           -           -
TN
F α
Pr
od
uc
tio
n
 (p
g/
m
l)
0
200
400
600
*
##
Thymoquinone (10 μM)          -          -           +          -           +
LPS (100 ng/ml)                     -          +          +          +          +
SIRT1 siRNA                          -           -          -           +          +
Control siRNA                       +          +         +           -           -
IL
-6
 P
ro
du
ct
io
n
 (p
g/
m
l)
0
100
200
300
400
500
**
##
Thymoquinone (10 μM)          -          -           +          -           +
LPS (100 ng/ml)                     -          +          +          +          +
SIRT1 siRNA                          -           -          -           +          +
Control siRNA                       +          +         +           -           -
IL
-1
β P
ro
du
ct
io
n
 (p
g/
m
l)
0
5
10
15
20
**
##
Thymoquinone (10 μM)          -          -           +          -           +
LPS (100 ng/ml)                     -          +          +          +          +
SIRT1 siRNA                          -           -          -           +          +
Control siRNA                       +          +         +           -           -
N
O
 P
ro
du
ct
io
n
 ( μ
M
)
A B
C D
0
5000
10000
15000
*** ns
Thymoquinone (10 μM)          -          -           +          -           +
LPS (100 ng/ml)                     -          +          +          +          +
SIRT1 siRNA                          -           -          -           +          +
Control siRNA                       +          +         +           -           -
C
el
lu
la
r 
R
O
S 
Pr
od
uc
tio
n
(R
LU
)
0
100
200
300
400
*
#
Thymoquinone (10 μM)          -          -           +          -           +
LPS (100 ng/ml)                     -          +          +          +          +
SIRT1 siRNA                          -           -          -           +          +
Control siRNA                       +          +         +           -           -
PG
E 2
 P
ro
du
ct
io
n
 (p
g/
m
l)
0.0
0.5
1.0
1.5
2.0
***
###
Thymoquinone (10 μM)          -          -           +          -           +
LPS (100 ng/ml)                     -          +          +          +          +
SIRT1 siRNA                          -           -          -           +          +
Control siRNA                       +          +         +           -           -
N
F-
κ
B
 D
N
A
 B
in
di
ng
 (O
D
)
E F
G
Fig. 7 Inhibition of neuroinflammation by thymoquinone is depen-
dent on SIRT1. Control siRNA- and SIRT1 siRNA-transfected BV2
cells were pre-treated with thymoquinone (10 lM) prior to stimula-
tion with LPS (100 ng/ml) for 24 h. Culture supernatants were
analysed for TNFa (a), IL-6 (b), IL-1b (c), nitrite (d) and PGE2 (e). In
f nuclear extracts from cells were added to 96-well plates to which an
oligonucleotide containing the NF-jB consensus site (50-
GGGACTTTCC-30) has been immobilised, followed by addition of
NF-jB and HRP-conjugated antibodies. Absorbance was read in a
microplate reader. Reduction of cellular ROS production in LPS-
stimulated microglia is not dependent on SIRT1 (g). (Mean ± SEM;
**p\ 0.01, ***p\ 0.001 thymoquinone ?LPS treatment compared
with LPS (alone) in control siRNA-transfected cells; #p\ 0.05,
###p\ 0.001, thymoquinone ? LPS treatment in SIRT1 siRNA-
transfected cells compared with thymoquinone ? LPS treatment in
control siRNA-transfected cells; one-way ANOVA)
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AMPKa-dependent mechanisms. Similar observations
have been reported for berberine [34], ginseng [35] and
paeonol [36]. We suggest that activation of AMPK possi-
bly contributes to inhibition of neuroinflammation by
thymoquinone, which sheds more light on the mechanisms
involved in the activity of this compound.
It has been reported that AMPK activation can promote
expression of genes which are involved in antioxidant
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Fig. 8 Inhibition of neuroinflammation by thymoquinone was abol-
ished in the presence of EX527. BV2 cells were treated with EX527
(1 lM), followed by thymoquinone (10 lM) and LPS (100 ng/ml) for
24 h. Culture supernatants were collected and analysed for TNFa (a),
IL-6 (b), IL-1b (c), nitrite (d) and PGE2 (e). In f nuclear extracts from
cells were added to 96-well plates to which an oligonucleotide
containing the NF-jB consensus site (50-GGGACTTTCC-30) has
been immobilised, followed by addition of NF-jB and HRP-
conjugated antibodies. Absorbance was read in a microplate reader.
Reduction of cellular ROS production by thymoquinone was not
abolished in the presence of EX527 (G). (Mean ± SEM; **p\ 0.01,
***p\ 0.001 compared with LPS stimulation; #p\ 0.05, ##p\ 0.01,
###p\ 0.001, EX527 ? thymoquinone ? LPS treatment compared
with thymoquinone ? LPS treatment; one-way ANOVA)
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defence mechanisms [37]. Also, AMPK activation has been
shown to increase NAD? levels, resulting in SIRT1 acti-
vation and deacetylation-induced activation of targets such
as FOXO3a [38]. Interestingly, AMPK activation has been
linked to nuclear accumulation of the antioxidant tran-
scription factor Nrf2 [24, 39]. Studies have also shown that
upregulation of AMPK abolished the levels of LPS-en-
hanced NOX-derived ROS in human brain microvascular
endothelial cells [40]. Our results showing that inhibition
of ROS by thymoquinone is reversed in the presence of
AMPK gene knockout and compound C seem to suggest
that activation of AMPK is likely involved reducing LPS-
induced ROS generation, and contributes to the antioxidant
activity of the compound.
It is now known that inhibition of neuroinflammation
could be achieved through processes involved in the
deacetylation of p65. The NAD?-dependent deacetylase
SIRT1 is known to deacetylate p65, resulting in the inhi-
bition of the transcriptional ability of NF-jB [11], and the
resulting appearance of pro-inflammatory genes. We
therefore became interested in establishing whether this
could be linked to a direct effect of the compound on
SIRT1. Interestingly, thymoquinone treatment induced
significant accumulation of SIRT1 protein in the nucleus of
BV2 microglia, while inducing its disappearance from the
cytoplasm. The compound also increased the levels of
NAD? in the cells, suggesting an NAD-dependent activa-
tion of SIRT1. These results suggest that thymoquinone
could be blocking LPS-induced p65 acetylation through a
direct activation of SIRT1, which then deacetylates the
protein. The natural SIRT1 activator, resveratrol, has been
similarly shown to target NF-jB activation by promoting
deacetylation of RelA/p65 in Ab-stimulated microglia [12].
Resveratrol has also been shown to inhibit inflammatory
response through attenuation of LPS-induced production of
NO, PGE2, iNOS, COX-2, TNFa, IL-1b, as well as inhi-
bition of NF-jB activation in BV2 microglia [41]. We
further established that SIRT1 gene knockout and EX527
treatment resulted in the loss of anti-inflammatory but not
antioxidant activity of thymoquinone in LPS-activated
BV2 microglia. These observations further confirm that
thymoquinone activates SIRT1 in the nucleus, resulting in
the deacetylation and nuclear export of p65 NF-jB. This
results in suppression of transcription of NF-jB-controlled
pro-inflammatory genes such as TNFa, IL-6, IL-1b, as well
as COX-2 and iNOS. Our results are similar to those
obtained in a study reported by Yang et al., which shows
that thymoquinone enhanced SIRT1 protein levels in
human hepatic stellate cells [32].
We further showed that NAD?-dependent activation of
SIRT1 by thymoquinone requires AMPK. This further
suggests a possible interaction between SIRT1 and AMPK
in the activity of thymoquinone in BV2 microglia. This
interaction may account for the anti-inflammatory activity
of the compound in LPS-activated microglia (Fig. 10).
This study has established that thymoquinone inhibits
NOX-mediated ROS generation and activates both AMPK
and SIRT1 in BV2 microglia. These actions are proposed
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Fig. 9 Activation of NAD?-dependent SIRT1 by thymoquinone was
abolished in the presence of compound C. BV2 cells were treated with
compound C (10 lM), followed by thymoquinone (10 lM) for 24 h.
Cell extracts were analysed for nuclear SIRT1 (a, b) and NAD?/
NADH (c). Data and densitometric analyses of three independent
experiments are shown (Mean ± SEM; *p\ 0.05, **p\ 0.01; one-
way ANOVA)
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to contribute to the anti-inflammatory activity of the
compound in activated microglia. Further studies are
required to determine whether this compound activates
SIRT1 in neurons to produce neuroprotective effects.
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